Use of Implanted Epidural Catheter for Opioid Delivery Appears Safe, Effective in Home Setting

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

NEW YORK-An implanted epidural catheter can be a safe and effective means of providing analgesia in the home setting for patients with advanced cancer, Memorial Sloan-Kettering Cancer Center researchers found in a retrospective review.

NEW YORK-An implanted epidural catheter can be a safe and effectivemeans of providing analgesia in the home setting for patientswith advanced cancer, Memorial Sloan-Kettering Cancer Center researchersfound in a retrospective review.

Angela Racolin, RN, and her colleagues in the Anesthesiology PainManagement Group examined the charts of 40 cancer patients referredfor management of inadequate analgesia or intolerable opioid sideeffects.

These patients lived an average of 2.3 months after catheter implantation,with 85% dying at home, the majority with satisfactory pain reliefprovided by the epidural till the end.

"Most patients do deteriorate as their disease progresses,requiring multiple dosage changes," Ms. Racolin said in aninterview, "but we can usually do that with the home careagencies over the telephone, so patients can remain in their homes."

In her poster presentation, Ms. Racolin said that in this seriesof patients, there were no serious complications associated withthe epidural catheters or with the medications used-hydromorphone(Dilaudid), morphine, and fentanyl (Sublimaze).

One catheter had to be removed due to infection 7 months afterinsertion, and one catheter became dislodged 6 weeks after implantation.

Cost analysis showed an average charge of $200 to $600/day, dependingon the choice of analgesic drug and home care company. In thesepatients, with a life expectancy of 2.3 months, the total costper patient of epidural drug delivery with home nursing care rangedfrom $21,000 to $42,000.

"In our practice, there are patients who can't tolerate sufficientoral or parenteral medication to keep them comfortable, and theother options, such as regional nerve block or periodic epiduralbolus doses, may not be appropriate," she said. "Forthese patients, we view epidural delivery as a very viable, albeitexpensive, option."

Although less invasive methods are always tried first, "thecontroversy," she said, "is, how long do you put a patientthrough trials of different opioids before you go to an epidural?I don't think anyone has definitive guidelines about this, andit's going to be different for different people with differentkinds of disease."

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content